There is a small piece of blue plastic on the table in front of Ahmet Tutuncu. It is not decorative. In the portrait, the San Diego light is soft, his sleeves are rolled, and the device in his hand looks almost comically modest beside the scale of the pharmaceutical machinery behind it. Yet this is where his career lives: at the last inch between a carefully developed compound and an ordinary person trying to use it correctly.
Tutuncu has spent more than three decades in respiratory science, medical affairs, clinical development, and company-building. His résumé has the geography of a physician-scientist in motion: Istanbul, Rotterdam, San Diego. Its corporate chapters include Alliance Pharmaceutical, SkyePharma, Verus, Elevation, Patara, and now AeroRx Therapeutics. But the more revealing map is conceptual. Again and again, he has returned to delivery - the awkward, physical business of how medicine leaves its container and reaches its destination.
Biotechnology often writes its drama at the molecular level. Tutuncu’s work insists on a less glamorous truth. A molecule can be sound, a trial can be carefully designed, and a regulatory strategy can be coherent, while the human being at the end of the process still has to coordinate breath, hand, timing, and hardware. Elegance on a slide is not the same thing as ease at a kitchen table.
“Delivery is not a secondary consideration, it’s central to whether treatment works at all.”Ahmet Tutuncu
The clinic came before the company
Tutuncu received his medical degree from the University of Istanbul and trained in critical care medicine. He went on to earn a PhD in respiratory pathophysiology at Erasmus University Rotterdam. Before business titles accumulated, there was academic medicine: an assistant professorship in Istanbul and published work on respiratory mechanics, including the pressure-volume behavior of mechanically ventilated lungs.
That sequence matters. His later companies did not begin with a general wish to “disrupt healthcare,” that scented candle of pitch-deck language. They began with the stubborn mechanics of breathing and delivery. The early research looked at what pressure, volume, and timing do inside the respiratory system. The later work asked a related commercial question: how should a therapy be designed when the person using it cannot reliably perform the choreography demanded by a handheld inhaler?
A career measured in air miles and airway mechanics
Industry gave him a different laboratory. At Alliance Pharmaceutical he took on roles of increasing responsibility. At SkyePharma he became director of corporate medical affairs and medical director for pulmonary products, developing clinical plans around late-stage respiratory programs. In January 2006, Verus Pharmaceuticals hired him as vice president of medical affairs. The appointment announcement credited him with 20 years across practice and corporate medicine. By then, the arc from bedside physiology to drug-device development was already visible.
His professional affiliations also spanned the scientific and industrial sides of the field. By 2006, he belonged to the American Thoracic Society, the European Respiratory Society, and the Academy of Pharmaceutical Physicians and Investigators. Twenty years later, he would present AeroRx data at the American Thoracic Society’s international conference and prepare analyses for the European society’s congress. The memberships had become venues; the academic interests had become programs. It is a tidy loop, although anyone who has waited through a clinical-development calendar would object to the word “tidy.”
Three companies, one recurring question
In 2008, Tutuncu co-founded Elevation Pharmaceuticals with Cam Garner and Bill Gerhart. The company’s initial focus was tightly defined: inhaled products for a group poorly served by dry-powder and metered-dose inhalers. It raised $30 million in Series A financing in 2010 and advanced an inhalation solution delivered through a portable nebulizer.
Sunovion acquired Elevation in September 2012. The deal included $100 million up front, with additional payments tied to development and commercial milestones. Elevation became Sunovion Respiratory Development, and its lead program continued down the long regulatory road. The product later known as Lonhala Magnair became one of three successful respiratory applications that AeroRx credits to development activities involving Tutuncu. The other two were Flutiform pMDI and Pulmicort HFA pMDI.
Then came Patara Pharma, incorporated in 2013. Tutuncu co-founded the company and served as chief medical officer. Its inhaled platform produced peer-reviewed clinical work and another lesson in how much the device and formulation can matter together. Roivant acquired Patara in 2018, and the business became Respivant Sciences.
A pattern this clean can look inevitable after the fact. It was not. Each venture still had to translate a narrow observation into chemistry, clinical design, regulatory argument, financing, and a team willing to endure years of uncertain progress. What repeated was not the outcome but the choice of problem. Tutuncu kept betting that delivery was not a footnote to the therapy. It was part of the therapy’s design.
The third pass
AeroRx Therapeutics is the third expression of that thesis. Based in La Jolla’s Avalon BioVentures Accelerator, the company is built around a compact internal operation and a roster of specialists spanning pharmaceutical development, regulatory affairs, aerosol science, product development, and business development. Its SEC filing lists Tutuncu as executive officer and director. On the company site, his title is simpler: CEO and co-founder.
The names around him reveal how a small biotech expands its reach without pretending to be a large one. John Lord, Paul Laskar, and Mei-chang Kuo cover pharmaceutical development. Peter Fernandes works on regulatory and quality matters; Nani Kadrichu on aerosol science and delivery; Thomas Tarara leads product development; Bryce Suchomel handles business development. Corporate filings connect Tutuncu with directors Sanford Madigan, John Patton, Heather Preston, and investor Jay Lichter, while Reardon Tighe is listed as an executive officer. This is less an army than a carefully arranged dinner party, provided the dinner conversation concerns formulations, pharmacokinetics, and federal paperwork.
The lead program, AERO-007, combines two established long-acting compounds in a solution delivered through a standard jet nebulizer. The business argument is a matter of interface design. Combination therapy is commonly delivered through handheld inhalers, while the nebulized market has lacked the equivalent fixed-dose combination. AeroRx is trying to put those pieces together without requiring proprietary hardware.
In July 2025, the company reported positive topline results from a Phase 2a crossover study. The full data were presented by Tutuncu at the American Thoracic Society conference in May 2026. Sixteen participants received two dose levels and placebo in separate periods, with serial measurements over 24 hours. The company reported sustained activity at both dose levels and no discontinuations caused by adverse events.
Three months after the topline announcement, AeroRx closed a $21 million Series A led by Avalon BioVentures, joined by Correlation Ventures, Alexandria Venture Investments, and other backers. The money is intended for a Phase 2b dose-optimization study and preparation for later-stage development. A second program, AERO-111, is earlier in the pipeline.
The announcement carried a Tutuncu signature familiar from his public comments: gratitude distributed broadly. “I am grateful to the patients, investigators, advisors, and AeroRx team who made this study possible.” It is the language of someone who knows that a founder may hold the microphone while a clinical program is always plural.
What repetition teaches
In January 2026, Tutuncu appeared on The BioHub podcast for a 24-minute conversation about AeroRx and the recent burst of deal-making in respiratory biotechnology. The interesting subtext was his own record. Elevation and Patara had both found acquirers for inhaled-drug platforms. AeroRx had just raised its institutional round. He was not watching the cycle from the cheap seats.
Repeat founders are often praised for speed: the old contacts answer, the pitch sharpens, the avoidable mistakes become slightly more avoidable. Tutuncu’s record suggests another advantage. Repetition creates a private archive of interfaces - between scientist and regulator, formulation and device, study design and financing, boardroom ambition and clinical patience. The third company does not begin at zero, even when its balance sheet once did.
There is restraint in the AeroRx strategy. It combines validated active ingredients, uses a standard jet nebulizer, and aims at a clearly described delivery gap. The novelty lives in the formulation and combination, but the pitch does not require science fiction. This is innovation with its sleeves rolled up. The question is not whether the future can be invented from scratch. It is whether the present can be made less demanding.
Tutuncu’s career has narrowed toward that question for 30 years. The physician saw the physiology. The scientist studied the mechanics. The medical-affairs executive learned the regulatory route. The founder assembled those experiences into companies. Each role brought him closer to the small blue object on the table.
Biotech’s public moments are financings, trial readouts, conference presentations, and acquisitions. Its private work is a procession of tolerances, protocols, formulations, devices, and forms. Tutuncu has chosen to live in both worlds. He can discuss the market’s appetite for respiratory deals, then return to the humble matter of how someone breathes through a machine.
The last inch is rarely the part that looks impressive from a distance. Up close, it is where the whole enterprise either becomes usable or remains an elegant idea. Ahmet Tutuncu keeps working there.
Follow the work